Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EdgeRx vs Remi Meds

By GLP-1 ScorecardUpdated

EdgeRxFactor scores not reassessed.
Site position #42

Higher score

Remi MedsFactor scores not reassessed.
Site position #510

Lower score

Score comparison

EdgeRx has the higher recorded score — 79/100 to 48.4/100.

EdgeRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EdgeRx lists compounded GLP-1 injections in a men’s health program. Its terms say the final charge can vary with the prescription and pharmacy.

Before you choose

Before comparing the headline prices, the EdgeRx review and the Remi Meds review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, EdgeRx vs Renlo Health and Independent Wellness vs Remi Meds compare each of them with another graded program, and the list of alternatives to EdgeRx ranks the programs closest to EdgeRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Oak review covers one graded close to these two, at 63.2/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueEdgeRx +36
70
34
Dose & formulationEdgeRx +21
75
54
Clinical oversightEdgeRx +34
88
54
Labs & monitoringEdgeRx +28
78
50
FulfillmentEdgeRx +37
90
53
Contract termsEdgeRx +25
80
55
EdgeRx · top barRemi Meds · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEdgeRxRemi Meds
WeighScore79/10048.4/100
GradeC+C
Site position#42#510
SemaglutideAdvertised $199/mo; confirm final prescription charge$249/mo (0.25 mg dose, compounded)
TirzepatideAdvertised $225/mo; confirm final prescription charge$349/mo (2.25 mg dose, compounded)
Coverage47 states advertised; excludes Arkansas, Indiana and South CarolinaCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
EdgeRx

Site position #42 · C+

Factor scores not reassessed.

Strengths

  • Publishes separate semaglutide and tirzepatide prices
  • Names Strive as its primary 503A pharmacy in its terms
  • Advertises included shipping and physician review

What to consider

  • The final charge may vary with the prescribed product and dispensing pharmacy
  • The homepage’s approval refund language needs to be reconciled with the consultation fee and final-sale terms
Remi Meds

Site position #510 · C

Factor scores not reassessed.

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

What to consider

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard